0001209191-23-006324.txt : 20230202 0001209191-23-006324.hdr.sgml : 20230202 20230202175647 ACCESSION NUMBER: 0001209191-23-006324 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230201 FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gros David-Alexandre C CENTRAL INDEX KEY: 0001644489 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36620 FILM NUMBER: 23582617 MAIL ADDRESS: STREET 1: 220 MARLBOROUGH STREET STREET 2: #6 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eledon Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-238-8090 MAIL ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: Novus Therapeutics, Inc. DATE OF NAME CHANGE: 20170511 FORMER COMPANY: FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc DATE OF NAME CHANGE: 20070622 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-01 0 0001404281 Eledon Pharmaceuticals, Inc. ELDN 0001644489 Gros David-Alexandre C C/O ELEDON PHARMACEUTICALS, INC. 19900 MACARTHUR BLVD STE. 550 IRVINE CA 92612 1 1 0 0 Chief Executive Officer Stock Option (right to buy) 3.08 2023-02-01 4 A 0 300000 0.00 A 2033-02-01 Common Stock 300000 300000 D Stock Option (right to buy) 3.97 2023-02-01 4 A 0 153600 0.00 A 2032-02-01 Common Stock 153600 153600 D This option represents a right to purchase up to 300,000 shares of Common Stock, which options vests with respect to 75,000 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending February 1, 2027. This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on February 1, 2022. The option satisfied the performance criteria with respect to 153,600 shares of underlying Common Stock and these credited shares will satisfy the time-based vesting criteria with respect to 38,400 shares of Common Stock on February 1, 2023, and then with respect to 1/48th of the credited shares monthly over the three-year period ending February 1, 2026. /s/ David-Alexandre C. Gros 2023-02-02